Newsletter
Earnings
Interviews
Transcripts
×
Menu
Home
Earnings
Interviews
Transcripts
IPO
Tech
Biotechnology
BIIB Earnings: Biogen Q1 2025 adj. profit drops despite higher revenues
May 1, 2025
Infographic: How Eli Lilly (LLY) performed in Q1 2025
May 1, 2025
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
April 25, 2025
Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops
April 24, 2025
MRK Earnings: Merck & Co. Q1 adj. profit rises, beats estimates
April 24, 2025
Earnings: Intuitive Surgical (ISRG) reports higher revenue and profit for Q1 2025
April 23, 2025
Abbott Laboratories (ABT) Q1 2025 Earnings: Key financials and quarterly highlights
April 16, 2025
OS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul Romness
March 25, 2025
Illumina (ILMN) expects adjusted EPS of approximately $4.50 for FY25
March 11, 2025
Earnings Summary: Moderna slips to loss in Q4; revenue down 66%
February 17, 2025
Key metrics from Biogen’s (BIIB) Q4 2024 earnings results
February 12, 2025
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
February 6, 2025
LLY Earnings: Eli Lilly Q4 2024 profit more than doubles; revenue up 45%
February 6, 2025
MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth
February 4, 2025
AbbVie Q4 2024 adjusted earnings decline despite 6% revenue growth
January 31, 2025
Earnings Summary: DexCom reports preliminary Q4 2024 results
January 14, 2025
NeOnc Technologies plans to go public through direct listing
January 7, 2025
Walgreens Boots Alliance expected to report mixed Q1 2025 results
January 2, 2025
“Gelteq has been continuously evolving to expand applications and audiences”
December 18, 2024
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
December 17, 2024
Earnings Summary: A snapshot of CooperCompanies (COO) Q4 2024 results
December 6, 2024
Posts pagination
« Previous
1
2
3
4
…
25
Next »
Top